So Astra-Zeneca, not Prana, won Takeda's Parkinson's partnership prize. They recognized AZN's $15.22 billion market cap vs PRAN's $29.36 million, and AZN's 59,700 employees vs PRAN's 13 employees. Wonder how that PD gut neurodegeneration collaboration is going for Takeda and PRAN.
Release Date: 31/08/17 16:45 Summary: Appendix 4E and Annual Report Price Sensitive: Yes Download Document 2.09MB
Buyers' Doldrums - Where's the volume? Any sign of interest?
PBT.AX showed no trades Aug 1, 9, 10, 22, 24....5 days of 21 trading days (23.8% no trades) Closed $0.053 again.
RALLYYYYYYYYYYYYY on this stock : SLNO (MC $16 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $16 Million Cash: $8 Million Price $0.35
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Crush the NASDAQ & NYSE with the Blggest Wlnners from PennySt0ck1O1.0rg
Somebody shaking the tree. Down 12 % during the last hour.
“Sig-1” and the Reversal of “79-Year-Old Grandma’s Alzheimer’s” pitched by Casey | Stock Gumshoe
Closed at near low of day but volume remains fairly low @77,299 shares as compared with daily average 91,704 shares. No post-market trading so far. Prana rumors usually go the other way - temporarily up instead of this dip.
Beware those who ignore statistics but claim superiority with nothing to sell PRAN........$20.8M market capitalization LLY............$87.415B PFE...........197.83B JNJ............335.181B MRK..........176.35B
Anyone familiar with this research? Binghampton Univ. just announced a Parkinson's drug:
New drug may treat and limit progression of Parkinson's disease
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.
Scott Ayton, Amir Fazlollahi, Pierrick Bourgeat, Parnesh Raniga, Amanda Ng ... Published: 26 July 2017 Abstract See Derry and Kent (doi:10.1093/awx167) for a scientific commentary on this article. The large variance in cognitive deterioration in subjects who test positive for amyloid-β by positron emission tomography indicates that convergent pathologies, such as iron accumulation, might combine with amyloid-β to accelerate Alzheimer’s disease progression. Here, we applied quantitative susceptibility mapping, a relatively new magnetic resonance imaging method sensitive to tissue iron, to assess the relationship between iron, amyloid-β load, and cognitive decline in 117 subjects who underwent baseline magnetic resonance imaging and amyloid-β positron emission tomography from the Australian Imaging, Biomarkers and Lifestyle study (AIBL). Cognitive function data were collected every 18 months for up to 6 years from 100 volunteers who were either cognitively normal (n = 64) or diagnosed with mild cognitive impairment (n = 17) or Alzheimer’s disease (n = 19). Among participants with amyloid pathology (n = 45), higher hippocampal quantitative susceptibility mapping levels predicted accelerated deterioration in composite cognition tests for episodic memory [β(standard error) = −0.169 (0.034), P = 9.2 × 10−7], executive function [β(standard error) = −0.139 (0.048), P = 0.004), and attention [β(standard error) = −0.074 (0.029), P = 0.012]. Deteriorating performance in a composite of language tests was predicted by higher quantitative susceptibility mapping levels in temporal lobe [β(standard error) = −0.104 (0.05), P = 0.036] and frontal lobe [β(standard error) = −0.154 (0.055), P = 0.006]. These findings indicate that brain iron might combine with amyloid-β to accelerate clinical progression and that quantitative susceptibility mapping could be used in combination with amyloid-β positron emission tomography to stratify individuals at risk of decline.
This is more like it. Takeda, market cap $40billion, now on board with PBT434 development. Been waiting for a Pharma to recognize the potential of Prana's MPACs for some time. From one year ago: [NEW YORK (TheStreet) -- Takeda Pharmaceutical (TKPYY) is looking for potential multi-billion dollar deals in the U.S. and other overseas markets as the Japanese pharmaceutical giant seeks to lower its dependence on sluggish domestic sales.
Takeda CEO Christophe Weber would not confirm earlier reports that the company had set aside $10 billion to $15 billion for acquisitions, according to Reuters. Weber said the company is exploring more deals as Takeda has refocused several initiatives and is overhauling its research activities.] Looks like they just spotted the bargain of the decade. IMO
Is PRAN selling at cash value? That's quite amazing given her potentials.
If we are to go off the RSI then you could argue that a pull back next day or so could occur on PRAN before rallying up. if you guys have questions you should ask awe*some*stock*s. They often respond to my emails which is helpful.
KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.